Navigation Links
Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
Date:12/20/2007

REDWOOD CITY, Calif., Dec. 20 /PRNewswire/ -- Pearl Therapeutics, Inc., a biopharmaceutical company developing treatments for major respiratory diseases, today announced the appointment of Colin Reisner, MD, FCCP, FAAAAI to the position of Chief Medical Officer and Executive Vice President of Clinical Development and Medical Affairs, and Michael Golden to the position of Vice President, Regulatory Affairs and Quality.

"We are delighted to welcome Colin and Michael as we continue to build our team with experts in the development of respiratory products," said Adrian Smith, President, Pearl Therapeutics, Inc. "Both Colin and Michael have proven records of success in the pharmaceutical industry and are innovative leaders who have designed and managed the clinical and CMC development programs of many marketed products, from pre-clinical through NDA filing and commercialization."

Dr. Reisner joins Pearl from Novartis Pharmaceuticals where he was Executive Director and former Disease Area Section Head for Global Respiratory Development, a position focused on both clinical development leadership and shaping Novartis' global strategy for respiratory products. He led the clinical development activities of several programs in asthma, COPD, and cystic fibrosis, assessing single and combination therapies across a wide range of delivery systems and dosage forms. Earlier at Novartis, Dr. Reisner served as the Global Brand Medical Director for Xolair(R), the first biologic agent approved for asthma. In this capacity, he oversaw all clinical activities ranging from design and implementation of the pediatric development program to the European approval for the treatment of severe persistent allergic asthma.

Prior to Novartis, Dr. Reisner served as Senior Director in the Respiratory Division at GlaxoSmithKline, and as the International Project Leader for beta agonists. Dr. Reisner played a diverse and integral role in the development of several key product
'/>"/>

SOURCE Pearl Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pearl Therapeutics Raises $15.5 Million in Private Financing
2. String of fullerene pearls
3. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
4. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
5. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
6. Nile Therapeutics, Inc. Adds to Executive Management Team
7. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
8. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
9. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
10. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
11. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - Resverlogix Corp. ... common shares of Resverlogix have approved the resolutions ... Capital Limited of 5,600,000 units at a price ... each unit being comprised of one common share ... proceeds of approximately CAD$15 million; and (ii) the ...
(Date:6/30/2015)... ... June 30, 2015 , ... uBiome and OpenBiome Partner for ... of fecal microbiota transplantation in C. difficile patients. , SAN FRANCISCO, uBiome and ... fecal microbiota transplantation (FMT) as a treatment for Clostridium difficile infections (C. diff). ...
(Date:6/30/2015)... , June 30, 2015  The University ... in Biosciences (CCE/Bio) and UC San Diego Extension ... to be held Aug.  12 – 14, 2015, ... This three-day workshop provides an intense exposure to ... biotechnology, and is well-suited to biologists, process engineers ...
(Date:6/30/2015)... ... June 30, 2015 , ... Smarter Alloys ... a revolutionary new archwire that allows orthodontists to simultaneously apply different forces to ... efficacy of SmartArch. “We’re thrilled about taking SmartArch one step closer to commercial ...
Breaking Biology Technology:Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2
... Sigma Life Science, the innovative biological ... SIAL ), today announced that its SAGE Labs initiative ... (ZFN) technology to generate knock-in rats in which foreign ... genome in a precisely targeted manner.  This breakthrough achievement ...
... QuantaLife, Inc. announced today that it ... of the proceeds will be used to establish commercial ... Digital™ PCR platform, into the life sciences research market ... tests. Paladin Capital Group, together with other existing investors ...
... YORK, Dec. 10, 2010 Ramius V&O Acquisition LLC, ... that it has sent a letter to the Board ... CYPB ) outlining its willingness to acquire all of ... $5.50 per share.  The offer is conditioned upon Cypress ...
Cached Biology Technology:Sigma® Life Science Creates World's First Knock-in Rats using Zinc Finger Nuclease Technology 2Sigma® Life Science Creates World's First Knock-in Rats using Zinc Finger Nuclease Technology 3Sigma® Life Science Creates World's First Knock-in Rats using Zinc Finger Nuclease Technology 4QuantaLife, Inc. Closes $17.2M Series B Financing to Accelerate Application Development for Its Droplet Digital™ PCR Platform and Establish Commercial Operations by 2011 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 3Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 4Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 5Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 6
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/25/2015)...  TAKE Solutions Ltd., a global business technology solutions ... Patent and Trademark Office (USPTO) for its "Method for ... Clinical Accelerators to reduce the time taken to standardize ... without the accelerators), thus reducing time to market. ... the heart of the patented Clinical Data Standardization Process ...
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... 2013 -- An important new study has revealed the ... influences gene expression profiles of breast cancer. The ... measurements may benefit from pooling of biopsies from a ... Cancer Conference in Brussels, Belgium. These findings represent ...
... Harbor, NY When a pedestrian hears the screech of a ... to move in response. Is the action taking place blocks ... truly primal mechanisms that we depend on every day of our ... sense of hearing -- is yielding its secrets to modern neuroscience. ...
... spill in the Gulf of Mexico, crude oil toxicity ... according to new findings from a research team that ... researchers from Louisiana and South Carolina, the scientists found ... locations show developmental abnormalities, including heart defects, delayed hatching ...
Cached Biology News:Study reveals magnitude of variation in gene expression measurements within breast cancers 2Study reveals magnitude of variation in gene expression measurements within breast cancers 3Scientists discover how brain's auditory center transmits information for decisions, actions 2Scientists discover how brain's auditory center transmits information for decisions, actions 3Health defects found in fish exposed to Deepwater Horizon oil spill 2
... tubes for rodent oral gavage feature soft ... perforation and trauma. Plus they are disposable, ... the risk of cross-contamination. ... 20ga Length: ...
Adult Bovine Serum US Origin...
... 13(S)-HODE-d4 contains 4 deuterium atoms at the ... intended for use as an internal standard for ... spectrometry. 13(S)-HODE is produced by incubation of linoleic ... been shown to inhibit the adhesion of tumor ...
...
Biology Products: